Skip to main content
Karo Pharma AB logo

Karo Pharma AB — Investor Relations & Filings

Ticker · KARO ISIN · SE0007464888 LEI · 213800G54Z51LOPGTA79 ST Manufacturing
Open in API
Filings indexed 653 across all filing types
Latest filing 2019-10-08 Report Publication Anno…
Country SE Sweden
Listing ST KARO

About Karo Pharma AB

https://www.karohealthcare.com/

Karo Pharma AB, operating as Karo Healthcare, is a healthcare company that develops, markets, and sells a broad portfolio of everyday healthcare products. The company's offerings are designed to prevent illness and treat common health problems, empowering consumers to manage their daily well-being. The portfolio consists of various branded medicines and consumer healthcare products distributed through pharmacies and directly to healthcare providers. With products available in over 90 countries, the company focuses on becoming a leading force in its sector by employing a consumer-centric approach, strategic innovation, and omnichannel excellence.

Recent filings

Filing Released Lang Actions
Karo Pharma senarelägger publiceringen av delårsrapporten för perioden januari – september 2019
Report Publication Announcement Classification · 99% confidence The document is a short announcement dated October 8, 2019, stating that Karo Pharma is postponing the publication of its interim report (delårsrapporten) for January-September 2019 from November 1st to November 15th, 2019. This is not the report itself (which would be an IR or 10-K), but an announcement about the timing of a future report's release. According to Rule 2 (The 'Menu vs Meal' Rule), a short document announcing the publication or timing of a report should be classified as a Report Publication Announcement (RPA).
2019-10-08 Swedish
Karo Pharma publishes prospectus relating to the rights issue
Capital/Financing Update Classification · 98% confidence The document is a press release dated September 30, 2019, announcing that the prospectus relating to a rights issue (fundraising activity) of approximately MSEK 2,003 has been approved and registered by the Swedish Financial Supervisory Authority. It explicitly states where the prospectus is available and provides details about the advisors. Since the document is an announcement about the publication of a prospectus related to a capital raising event (rights issue), it strongly aligns with the 'Capital/Financing Update' category (CAP). Although it mentions the publication of a prospectus, the core subject is the financing activity itself, which is more specific than a general 'Report Publication Announcement' (RPA). The document is short and focuses on the financing event and the availability of the related legal document (prospectus). Given the focus on a 'rights issue' and the associated fundraising amount, CAP is the most appropriate classification.
2019-09-30 English
Karo Pharma offentliggör prospekt avseende företrädesemissionen
Capital/Financing Update Classification · 98% confidence The document is a press release dated September 30, 2019, titled "Karo Pharma offentliggör prospekt avseende företrädesemissionen" (Karo Pharma publishes prospectus regarding the rights issue). It explicitly states that the prospectus for a rights issue (a financing activity) has been approved and registered by the Swedish Financial Supervisory Authority (Finansinspektionen) and provides links where the prospectus can be found. Since the document is an announcement about the publication of a prospectus related to a capital raising/financing event (rights issue), it strongly aligns with the 'Capital/Financing Update' category (CAP). Although it announces a prospectus, the core subject is the financing event itself, making CAP more specific than RPA or RNS. The document length (3688 chars) is short, but the content is a direct announcement of a major financing action (rights issue prospectus approval). Given the specific mention of 'företrädesemissionen' (rights issue), CAP is the most appropriate classification.
2019-09-30 Swedish
Karo Pharma beslutar om en fullt garanterad företrädesemission om cirka 2 miljarder kronor
Capital/Financing Update Classification · 98% confidence The document is a press release dated September 24, 2019, announcing that Karo Pharma has decided to conduct a fully guaranteed rights issue ('Företrädesemissionen') to raise approximately 2 billion SEK. This action involves issuing new shares to existing shareholders and details the subscription price, dates, and guarantees from major shareholders. This clearly falls under the category of corporate financing activities and capital structure changes. Reviewing the definitions: - 10-K/IR: Not an annual or interim financial report. - ER: Not an earnings release, but a financing announcement. - DIV/SHA/POS: While it involves shares, the primary purpose is raising capital via a rights issue, which is best captured by 'Capital/Financing Update'. - CAP (Capital/Financing Update): This definition covers 'Updates on company fundraising, financing activities, or capital structure changes.' The rights issue is a textbook example of a financing activity. - RPA/RNS: Although it is a press release, the content is substantive and specific to a financing event, making CAP a more precise classification than the general RPA or RNS fallback.
2019-09-24 Swedish
Karo Pharma resolves on a fully guaranteed rights issue of approximately SEK 2 billion
Capital/Financing Update Classification · 98% confidence The document is a press release announcing a 'fully guaranteed rights issue of approximately SEK 2 billion' by Karo Pharma. This action involves issuing new shares and details the subscription process, pricing, and shareholder rights. This clearly falls under the category of company fundraising, financing activities, or capital structure changes. Based on the definitions, this corresponds to 'Capital/Financing Update' (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). It is a direct announcement of a capital raising event.
2019-09-24 English
EXTRAORDINARY GENERAL MEETING IN KARO PHARMA AKTIEBOLAG ON 20 SEPTEMBER 2019
AGM Information Classification · 99% confidence The document explicitly mentions an 'EXTRAORDINARY GENERAL MEETING IN KARO PHARMA AKTIEBOLAG ON 20 SEPTEMBER 2019' and details a resolution passed at that meeting regarding authorizing the Board to issue new shares. This resolution directly relates to capital structure changes and financing (repayment of acquisition financing). While it occurs at a General Meeting, the core subject is a capital/financing resolution, which aligns best with 'Capital/Financing Update' (CAP). However, since the context is a formal resolution passed at a General Meeting, and the resolution itself is about a share issue (which could also suggest SHA), the primary driver here is the financing purpose. Given the options, 'CAP' covers the financing aspect, but the event is an EGM resolution. Since the resolution authorizes a future share issue (SHA) for financing (CAP), I must choose the most specific fit. A resolution passed at a meeting about a future share issue is often classified under the action it enables. Since the document details the resolution itself, and it is about authorizing a new issue of shares, 'SHA' (Share Issue/Capital Change) is a strong candidate. However, the text focuses heavily on the purpose: 'enable repayment of a part of the acquisition financing'. Let's re-evaluate the definitions. AGM-R is for presentations/materials *shared during* the AGM. This is a resolution announcement from the EGM. Since the resolution is specifically about authorizing a share issue, SHA is highly relevant. Given the context of a formal resolution announcement from a meeting, and the content being a direct authorization for a share issue, SHA is the most precise fit for the action authorized, even though it's announced via an EGM notice.
2019-09-20 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.